香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴該等 內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司法 權區內刊發或派發。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非，亦不構成於美國（定義見1933年《美國證券法》（「《證券法》」）S規例）出售證券的 要約或邀請及其任何部分。本公告或其任何內容或其副本亦不得攜進美國境內或於美國境內或 在刊發或派發本公告屬違法的任何其他司法權區內直接或間接派發。除非本公告所指證券根據 《證券法》辦理登記或獲豁免遵守《證券法》的登記規定，否則有關證券未曾亦不會根據《證券 法》登記，且不得在美國境內提呈發售、出售或以其他方式轉讓。本公司並無計劃在美國登記 本公告所述任何證券或在美國公開發售任何證券。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） ...

客户端 康龙化成（03759）午前股价上涨4.13%，现报25.20港元，成交额1.98亿港元。 康龙化成公布，该集团预期2025年实现营收约138.72亿-142.4亿元，同比增长13%-16%；归属于上市公 司股东的净利润约16.14亿-16.86亿元，同比下降6%-10%；扣非净利约15.07亿-15.62亿元，同比增长 36%-41%；经调整的非《国际财务报告准则》下归属于上市公司股东的净利润约17.675亿-18.48亿元， 同比增长10%-15%。 康龙化成（03759）午前股价上涨4.13%，现报25.20港元，成交额1.98亿港元。 康龙化成公布，该集团预期2025年实现营收约138.72亿-142.4亿元，同比增长13%-16%；归属于上市公 司股东的净利润约16.14亿-16.86亿元，同比下降6%-10%；扣非净利约15.07亿-15.62亿元，同比增长 36%-41%；经调整的非《国际财务报告准则》下归属于上市公司股东的净利润约17.675亿-18.48亿元， 同比增长10%-15%。 按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣 ...

康龙化成（300759）(03759)涨超4%，截至发稿，涨4.05%，报25.18港元，成交额1.23亿港元。 消息面上，康龙化成公布，该集团预期2025年实现营收约138.72亿-142.4亿元，同比增长13%-16%；归 属于上市公司股东的净利润约16.14亿-16.86亿元，同比下降6%-10%；扣非净利约15.07亿-15.62亿元， 同比增长36%-41%；经调整的非《国际财务报告准则》下归属于上市公司股东的净利润约17.675 亿-18.48亿元，同比增长10%-15%。 按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长14.79%、归属于上市公司股东的扣 除非经常性损益后的净利润同比增长54.09%、经调整的非《国际财务报告准则》下归属于上市公司股 东的净利润同比增长16.36%。 ...

消息面上，康龙化成公布，该集团预期2025年实现营收约138.72亿-142.4亿元，同比增长13%-16%；归 属于上市公司股东的净利润约16.14亿-16.86亿元，同比下降6%-10%；扣非净利约15.07亿-15.62亿元， 同比增长36%-41%；经调整的非《国际财务报告准则》下归属于上市公司股东的净利润约17.675 亿-18.48亿元，同比增长10%-15%。 按业绩预告中位值测算，2025年第四季度，公司营业收入同比增长 14.79%、归属于上市公司股东的扣 除非经常性损益后的净利润同比增长54.09%、经调整的非《国际财务报告准则》下归属于上市公司股 东的净利润同比增长16.36%。 智通财经APP获悉，康龙化成(03759)涨超4%，截至发稿，涨4.05%，报25.18港元，成交额1.23亿港元。 ...

经济观察网2026年1月13日，康龙化成（300759）发布2025年度业绩预告，预计2025年净利润16.14亿元 至16.86亿元，同比下降6%至10%；扣除非经常性损益后的净利润15.07亿元至15.62亿元，同比增长36% 至41%。 ...

Group 1 - The core viewpoint of the news highlights the performance of the TaiKang Medical Health Fund, which saw declines in its two share classes, with Class C down by 13.45% and Class A down by 13.02% in 2025 [2][3] - The top ten holdings of the TaiKang Medical Health Fund in the third quarter of 2025 included companies such as JingTai Holdings, Kanglong Chemical, Fangzhou Jianke, SanSheng Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [2] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., and has been with TaiKang since July 2019, becoming the fund manager on March 8, 2022 [2]

Group 1: Shanghai Pudong Development Bank - The bank reported a net profit of 50.017 billion yuan for 2025, an increase of 10.52% year-on-year [1][2] - Total operating income reached 173.964 billion yuan, reflecting a growth of 1.88% compared to the previous year [2] - The bank's total assets exceeded 1 trillion yuan, reaching 1,008.1746 billion yuan, a 6.55% increase from the previous year [3] Group 2: Dongpeng Beverage - Dongpeng Beverage expects a net profit between 4.34 billion and 4.59 billion yuan for 2025, representing a year-on-year growth of 30.46% to 37.97% [4] - The anticipated operating income is projected to be between 20.76 billion and 21.12 billion yuan, indicating a growth of 31.07% to 33.34% [4] Group 3: TCL Technology - TCL Technology forecasts a net profit of 4.21 billion to 4.55 billion yuan for 2025, marking a significant increase of 169% to 191% year-on-year [5][6] - The company expects to surpass 100 billion yuan in operating revenue, with net profit exceeding 8 billion yuan [5] Group 4: Changjiang Electric Power - Changjiang Electric Power reported a net profit of 34.167 billion yuan for 2025, a 5.14% increase year-on-year [8] - The total operating revenue for the year is expected to be 85.882 billion yuan, reflecting a growth of 1.65% [8] Group 5: China Gold - China Gold anticipates a net profit of 286 million to 368 million yuan for 2025, a decrease of 55% to 65% year-on-year [21] - The decline is attributed to market fluctuations and reduced consumer traffic [21] Group 6: LaKala - LaKala expects a net profit between 1.06 billion and 1.2 billion yuan for 2025, representing a growth of 202% to 242% year-on-year [22] - The increase is primarily due to significant investment income from stock holdings [22] Group 7: Baiwei Storage - Baiwei Storage projects a net profit of 850 million to 1 billion yuan for 2025, indicating a year-on-year increase of 427% to 520% [23] - The growth is driven by improved sales and gross margins in the AI sector [23] Group 8: Shengxin Lithium Energy - Shengxin Lithium Energy forecasts a net loss of 600 million to 850 million yuan for 2025, similar to the previous year's loss [24] - The company attributes the loss to industry supply-demand dynamics and increased exchange losses [24] Group 9: Zhongguancun Online - Zhongguancun Online expects a net loss of 580 million to 700 million yuan for 2025, a significant increase from the previous year's loss of 243 million yuan [25] - The losses are linked to increased promotional investments in overseas markets [25] Group 10: Huaxia Happiness - Huaxia Happiness anticipates a net loss of 16 billion to 24 billion yuan for 2025, a substantial increase from the previous year's loss of 4.817 billion yuan [26] - The decline is due to reduced project turnover and high financial costs [26]

Mergers and Acquisitions - Lianjian Technology plans to acquire 55% equity of Zhongding Testing for 101 million yuan, making it a subsidiary included in the consolidated financial statements after the transaction [1] Termination of Asset Purchase - Yaxing Chemical announced the termination of its plan to issue shares and pay cash for the acquisition of 100% equity of Shandong Tianyi Chemical, which was expected to constitute a major asset restructuring [2] Earnings Disclosure - Kanglong Chemical expects a net profit of 1.614 billion to 1.686 billion yuan for 2025, a year-on-year decrease of 6% to 10%, while revenue is projected to grow by 13% to 16% [3] - Yongyou Network anticipates a net loss of 1.3 billion to 1.39 billion yuan for 2025, reducing losses by 671 million to 761 million yuan year-on-year [4] - Dongpeng Beverage expects a net profit of 4.34 billion to 4.59 billion yuan for 2025, an increase of 1.013 billion to 1.263 billion yuan, representing a growth of 30.46% to 37.97% [5] - Pudong Development Bank forecasts a net profit of 50.017 billion yuan for 2025, a year-on-year increase of 10.52%, with revenue expected to be 173.964 billion yuan, up 1.88% [6] Shareholding Changes - Zhang Yijie, a shareholder of Jixin Technology, plans to reduce holdings by up to 969,030 shares, not exceeding 1% of the total share capital, for personal financial needs [8] - Quantum Leap, a shareholder of Zhangyue Technology, intends to reduce its stake by up to 438,900 shares, not exceeding 1% of the total share capital, due to personal needs [7] - Alibaba Health, a major shareholder of Shuyupingmin, plans to reduce its holdings by up to 810,720 shares, accounting for 2% of the total share capital, for personal financial needs [9] - Anyang Qixu, a shareholder of Xiangyu Medical, intends to reduce its stake by up to 480,000 shares, not exceeding 3% of the total share capital, due to personal financial needs [10] Risk Matters - *ST Lifang announced that its stock price has fallen below 1 yuan, which may lead to delisting due to the stock price being below par value, and it has received a notice of administrative penalty for false records in annual reports from 2021 to 2023 [11]

（文章来源：证券日报） 证券日报网讯 1月13日，康龙化成发布公告称，公司预计2025年营业收入1387162.56万元至1423989.89 万元，同比增长13%至16%；归属于上市公司股东的净利润161401.57万元至168574.98万元，同比下降 6%至10%。 ...

格隆汇1月13日丨康龙化成(03759.HK)公告，2025年，公司预计营业收入同比增长13%-16%、归属于上 市公司股东的扣除非经常性损益后的净利润同比增长36%-41%、经调整的非《国际财务报告准则》下归 属于上市公司股东的净利润同比增长10%-15%。在主营业务持续向好的情形下，主要由于非经常性损益 的下降，公司归属于上市公司股东的净利润相比上年同期下降6%-10%。 ...